ConforMIS Names President and CEO

ConforMIS Inc. announced today that Mark A. Augusti has been named the company’s president and CEO, effective Nov. 14.  The company expects Augusti to be appointed to the Board of Directors upon starting his employment.

Augusti will succeed current president and CEO Philipp Lang, M.D., who will continue to serve on the board.
 
Augusti’s 27-year business career has been marked with executive management responsibility in medical technology sales, marketing and general management. Augusti joined Integra LifeSciences Corporation in April 2014 and is now Integra’s corporate vice president and president of Orthopedics and Tissue Technologies, responsible for managing the division (which includes spine and extremity implants, orthobiologics, tissue products, and the private label business). His responsibilities include U.S. commercial leadership, global portfolio management, evaluation of corporate development opportunities and overall strategic direction. Prior to joining Integra, Augusti served as CEO of Bioventus LLC from May 2012 to August 2013, and was a member of the company’s Board of Directors during the same period. Prior to that Augusti spent nine years with Smith & Nephew plc., from April 2003 to April 2012, in a series of leadership roles, including president of the company’s Biologic Division, where he was appointed to lead Smith & Nephew’s new biologics initiative. He also served as Smith & Nephew’s president of the Orthopaedic Trauma & Clinical Therapies global business and senior vice president and general manager of the Trauma business. In 2000, Augusti joined J.P. Morgan Securities as a vice president in the private funds group. Prior to that, from 1987 to 2000, he spent 13 years at GE Medical Systems Inc., where he held various sales, marketing and strategic management roles, both in the United States and internationally.

“Mark Augusti’s experience and performance in a number of challenging roles was a significant factor in his selection as ConforMIS’ president and chief executive officer. Mark has led teams that delivered strong growth during his tenure at Integra,” said Kenneth P. Fallon, III, board chairman. “In Integra’s most recently reported quarter, Mark’s Orthopedics and Tissue Technologies division revenue grew 38 percent from the prior-year period for both the quarter and six-months ended June 30. Our board is looking forward to his commercial and operational leadership in unlocking the full value of our proprietary technology for customized joint implants.”

Augusti received his M.B.A. from the UCLA Anderson School of Management and his bachelor of science degree in computer science and economics from Duke University.
 
“I am extremely honored to be joining ConforMIS. I am impressed with this technology and value proposition for the advancement of joint arthroplasty,” Augusti said. “From my discussions with surgeons that use ConforMIS customized implants, it is clear to me that the clinical benefits gained from ConforMIS’ customized implant systems are tremendous—not only for patients, but for doctors and hospitals as well. Surgeons that use ConforMIS implants are passionate about the results they are achieving. I look forward to working with Dr. Philipp Lang and the ConforMIS board as we continue to move the company forward.”
 
“ConforMIS’ vision is ‘One Patient, One Implant’, each customized and designed to restore the natural shape of a patient’s knee. The clinical benefits to the patient paired with the potential for economic savings to the hospital, when compared to leading off-the-shelf brands, have helped transform ConforMIS into a rapidly growing medical device company,” Lang said. “Just a few weeks ago, we announced that we had sold over 50,000 customized knee implants since our inception, which represents a substantial increase over the 30,000 we had sold as of June of 2015 at the time of our IPO. This is a testament to our cutting-edge technology, and I am really excited about the prospects of ConforMIS as we move forward.”
 
“The Board appreciates Dr. Lang’s contributions to ConforMIS as founder and chief executive officer. Dr. Lang has been instrumental in building a great company, and we look forward to his continued contributions as a member of our board,” Fallon said,
 
ConforMIS uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient’s unique anatomy. ConforMIS offers a line of customized knee implants and pre-sterilized, single-use instruments delivered in a single package to the hospital. In recent clinical studies, ConforMIS iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Bedford, Mass.-based ConforMIS owns or exclusively in-licenses approximately 500 issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints.